SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Unleash Jugs

JUGS is capturing community attention as a new, low-holder crypto asset that speculators believe is primed for a potential squeeze due to high concentration among top addresses. Investors are actively discussing the coin's rapid price volatility and aggressive promotional campaigns, framing it as a high-risk, high-reward play.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors focus on its integration into the AI agentic economy and its recent transition toward a lower token inflation model. The community is actively debating the coin's potential as a long-term utility play, with many participants using market dips to accumulate positions while monitoring cross-chain interoperability developments.

Zoracles

Zoracles is facing intense community debate as holders balance frustration over recent price weakness with optimistic expectations for a potential V-shaped recovery tied to broader crypto market catalysts. Investors are actively discussing the impact of upcoming regulatory developments and liquidity shifts, while others use the current volatility as a dollar-cost averaging opportunity.

ETF Series Solutions - Defiance Quantum ETF

Defiance Quantum ETF

Quantum computing stocks are experiencing intense investor interest and volatility driven by reports of significant government investment aimed at accelerating the sector's development. While retail sentiment remains highly enthusiastic about the long-term potential for massive growth, many traders are turning to the Defiance Quantum ETF (QTUM) to gain diversified exposure to the space rather than attempting to navigate the high risks associated with individual quantum companies.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing heightened community engagement as investors debate its role within the broader meme coin ecosystem, with many participants pointing to historical price volatility and social media hype as catalysts. Traders are actively comparing it to other speculative assets, fueling ongoing speculation about potential price movements and its overall viability as a long-term holding.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad is capturing community attention through its long-standing cultural relevance and ongoing expansion into real-world fitness products, which investors are highlighting as a key differentiator. Enthusiastic supporters are actively discussing the project's brand longevity and potential for long-term growth as they share strategies for accumulating during market volatility.

Bitwise Hyperliquid ETF - Bitwise Hyperliquid ETF

Bitwise Hyperliquid ETF

BHYP is generating significant buzz as investors seek direct exposure to the Hyperliquid ecosystem, with the community highlighting its utility and institutional interest. Discussions are heavily focused on the ETF's recent debut, potential buying pressure, and comparisons to early-stage opportunities in major digital assets.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is gaining significant market attention as its modular edge data centers provide a strategic solution to the power and latency constraints currently hampering large-scale AI infrastructure projects. The community is actively discussing the company's competitive advantage in deploying these specialized units into underserved rural markets while securing recurring revenue contracts with major industry players.

Alamos Gold, Inc. is a Canadian-based intermediate gold producer. It operates through the following segments: Young-Davidson, Mulatos and Island Gold. The Young-Davidson, Mulatos and Island Gold segments represent its three operating mine sites. The company was founded on February 21, 2003 and is headquartered in Toronto, Canada.

Alamos Gold Inc. - Ordinary Shares - Class A

Alamos Gold (AGI) remains a focal point for investors as it executes a strategic acquisition of Argonaut Gold, a move designed to cement its status as a leading Canadian gold producer. The market is closely watching how the company integrates these new assets, with the community actively debating whether the recent consolidation and growth initiatives justify the current valuation against the backdrop of persistent gold demand.

Alcoa Corp. engages in the bauxite mining, alumina refining, and aluminum smelting and casting. It operates through the Alumina and Aluminum segments. The Alumina segment consists of a refining system, including the mining of bauxite, which is then refined into alumina, a compound of aluminum and oxygen that is the raw material used by smelters to produce aluminum metal. The Aluminum segment is composed of smelting and casthouse system. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.

Alcoa Corp

Alcoa is capturing investor interest as it navigates significant supply chain headwinds and structural tariff costs, while the community actively debates whether the stock is an undervalued industrial play or a value trap. Discussion is currently centered on how the company's asset utilization, including potential site conversions for data centers, balances against ongoing volatility in aluminum pricing and global geopolitical trade pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C meeting request from the...

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational...

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and...

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning...

Lantern Pharma Unveils Roadmap for withZeta.ai Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm and ZetaOmics

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, today unveiled the next phase of its development roadmap for withZeta.ai, the companys multi-agentic A.I...

Lantern Pharmas predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR AI platform, today announced the expansion of predictBBB.ai into a...

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic...

Emerging Data for Lantern Pharmas Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure With No Added Toxicity

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to...

Lantern Pharma Launches withZeta.ai the Worlds First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Lantern Pharma Inc. (Nasdaq: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai the worlds first and most comprehensive...

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

LTRN
Lantern Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest LTRN News

LTRNLantern Pharma Inc